Data for: Growth hormone supplementation may improve the pregnancy rate and endometrial receptivity for patients aged >40 years undertaking in vitro fertilization

This study included women aged > 40 years (range, 40–43 years) with previous experience of POR or poor ovarian reserve (POSEIDON group 4) undergoing their first ART treatment in our institution between January 2009 and March 2014. These patients were given the option of using GH, but may or may not have elected to utilize GH during the cycle when initially offered (due to costs or other concerns). This cohort study evaluated 182 cycles with and 160 without GH supplementation.

本研究纳入2009年1月至2014年3月期间，于本机构首次接受辅助生殖技术（Assisted Reproductive Technology, ART）治疗的女性受试者，纳入标准为年龄＞40岁（年龄区间为40~43岁），且既往存在卵巢低反应（Poor Ovarian Response, POR）或卵巢储备功能低下（属于POSEIDON分组4）。所有入组受试者均被提供了使用生长激素（Growth Hormone, GH）的治疗选择权，但因费用或其他顾虑，部分受试者在首次被提供该方案的治疗周期中，选择或未选择使用生长激素。本队列研究共评估了182个接受生长激素补充治疗的周期与160个未接受该类补充治疗的周期。